Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Novel therapies in AML: reason for hope or just hype?

Larkin K, Blum W.

Am Soc Clin Oncol Educ Book. 2014:e341-51. doi: 10.14694/EdBook_AM.2014.34.e341. Review.

2.

Targeting the c-kit receptor in the treatment of acute myelogenous leukemia.

Advani AS.

Curr Hematol Malig Rep. 2006 Jun;1(2):101-7. doi: 10.1007/s11899-006-0020-9. Review.

PMID:
20425339
3.

Core binding factor acute myeloid leukaemia and c-KIT mutations.

Riera L, Marmont F, Toppino D, Frairia C, Sismondi F, Audisio E, Di Bello C, D'Ardia S, Di Celle PF, Messa E, Inghirami G, Vitolo U, Pich A.

Oncol Rep. 2013 May;29(5):1867-72. doi: 10.3892/or.2013.2328. Epub 2013 Mar 5.

4.

Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.

Foran JM.

Hematology. 2012 Apr;17 Suppl 1:S137-40. doi: 10.1179/102453312X13336169156456.

PMID:
22507802
5.

Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.

Tettamanti S, Magnani CF, Biondi A, Biagi E.

Immunol Lett. 2013 Sep-Oct;155(1-2):43-6. doi: 10.1016/j.imlet.2013.09.013. Epub 2013 Sep 25. Review.

PMID:
24076117
6.

Challenges in Converting Acute Myeloid Leukemia (AML) Genomics Into AML Clinical Trials.

Caywood EH, Kolb EA.

J Clin Oncol. 2015 Dec 20;33(36):4238-9. doi: 10.1200/JCO.2015.63.9252. Epub 2015 Nov 16. No abstract available.

PMID:
26573081
7.

Receptor tyrosine kinase alterations in AML - biology and therapy.

Stirewalt DL, Meshinchi S.

Cancer Treat Res. 2010;145:85-108. doi: 10.1007/978-0-387-69259-3_6. Review.

PMID:
20306247
8.

The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.

Isidori A, Salvestrini V, Ciciarello M, Loscocco F, Visani G, Parisi S, Lecciso M, Ocadlikova D, Rossi L, Gabucci E, Clissa C, Curti A.

Expert Rev Hematol. 2014 Dec;7(6):807-18. doi: 10.1586/17474086.2014.958464. Epub 2014 Sep 16. Review.

PMID:
25227702
9.

New treatment for acute myelogenous leukemia.

DiNardo CD, Cortes JE.

Expert Opin Pharmacother. 2015 Jan;16(1):95-106. doi: 10.1517/14656566.2015.981527. Epub 2014 Dec 5. Review.

PMID:
25480777
10.

Endothelial cell derived angiocrine support of acute myeloid leukemia targeted by receptor tyrosine kinase inhibition.

Drusbosky L, Gars E, Trujillo A, McGee C, Meacham A, Wise E, Scott EW, Cogle CR.

Leuk Res. 2015 Sep;39(9):984-9. doi: 10.1016/j.leukres.2015.05.015. Epub 2015 Jul 2.

11.

Novel drug targets in acute leukemia.

Stock W.

Clin Adv Hematol Oncol. 2015 Aug;13(8):493-5. No abstract available.

PMID:
26351809
12.

Immunotherapeutic strategies for relapse control in acute myeloid leukemia.

Martner A, Thorén FB, Aurelius J, Hellstrand K.

Blood Rev. 2013 Sep;27(5):209-16. doi: 10.1016/j.blre.2013.06.006. Epub 2013 Jul 18. Review.

PMID:
23871358
13.

Molecular genetic pathways as therapeutic targets in acute myeloid leukemia.

Haferlach T.

Hematology Am Soc Hematol Educ Program. 2008:400-11. doi: 10.1182/asheducation-2008.1.400. Review.

PMID:
19074117
14.

Current and emerging therapies for acute myeloid leukemia.

Robak T, Wierzbowska A.

Clin Ther. 2009;31 Pt 2:2349-70. doi: 10.1016/j.clinthera.2009.11.017. Review.

PMID:
20110045
15.

Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?

Bernasconi P, Farina M, Boni M, Dambruoso I, Calvello C.

Am J Hematol. 2016 May;91(5):507-17. doi: 10.1002/ajh.24312. Epub 2016 Apr 4. Review.

16.

Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.

Larrue C, Saland E, Vergez F, Serhan N, Delabesse E, Mansat-De Mas V, Hospital MA, Tamburini J, Manenti S, Sarry JE, Récher C.

Mol Cancer Ther. 2015 Oct;14(10):2364-73. doi: 10.1158/1535-7163.MCT-15-0163. Epub 2015 Jul 23.

17.

Cytokines secreted by bone marrow stromal cells protect c-KIT mutant AML cells from c-KIT inhibitor-induced apoptosis.

Gordon PM, Dias S, Williams DA.

Leukemia. 2014 Nov;28(11):2257-60. doi: 10.1038/leu.2014.212. Epub 2014 Jul 17. No abstract available.

18.

Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials.

Sasine JP, Schiller GJ.

Blood Rev. 2015 Jan;29(1):1-9. doi: 10.1016/j.blre.2014.07.002. Epub 2014 Jul 16. Review.

PMID:
25441922
19.
20.

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.

Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB.

Cell Stem Cell. 2009 Jul 2;5(1):31-42. doi: 10.1016/j.stem.2009.04.018.

Supplemental Content

Support Center